None listed
Conditions
Brief summary
Macrolide antibiotics have beneficial effects in chronic infections of the lung, although apparently not due to antibacterial effects. We suspect that erythromycin in a low dose will alter inflammation in the lungs of subjects with bronchiectasis, and reduce the frequency of lung infections.
Interventions
Erythromycin (as ethylsuccinate salt) 400 mgs orally twice daily for 48 weeks
Sponsors
Dr David Serisier
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Bronchiectasis on high-resolution computed tomographic scans of the lungs 2. At least 2 pulmonary exacerbations in the preceding 12 months requiring antibiotic therapy 3. Chronic productive cough with daily sputum production 4. Clinically stable and no alteration to therapies in the 4 weeks preceding screening
Exclusion criteria
1. Cystic Fibrosis, tuberrculosis, non-tuberculous mycobacterial infection, focal endobronchial obstructing lesion 2. Smoking within the preceding 6 months 3. Maintenance oral antibiotic therapy 4. Any condition likely to result in a shortened life span within the 12 months of the study
Outcome results
None listed